Furthermore, we found that transiently elevating ROS production by targeting Glu‐GSH flux could activate immunoproteasome activity and increase MHC‐I antigen presentation in CRC cells, driving CD8+ T cell‐mediated anti‐tumor immune responses. This evidence concerns the gene CD8A and neoplasm.